Shire, the specialty pharma company, may need to find an antidote for a poison pill before it can win shareholders in Baxalta over to its $30bn bid.» Read More
As sports grapples with the effects of injuries, one area of medicine is looking to make pain and recovery a thing of the past.
The "Halftime Report" traders give their trades for the rest of the week
ACE will acquire Chubb in a cash and stock deal valued at $28.3 billion.
With Puerto Rico saying it can't pay its $72 billion debt, bond investors worry whether bond insurers can cover a looming default.
Andrew Sullivan, managing director of sales trading at Haitong International Securities, says Chinese banks and insurance firms have taken out some liquidity from the market as they proceed with their half-year audit.
The case revolves around subsidies that help reduce out-of-pocket costs for most Obamacare customers.
Insight to the impact to health coverage and the business community after the U.S. Supreme Court ruled same-sex couples can get married in all 50 states, with Todd Solomon, McDermott Will & Emery.
Dr. Toby Cosgrove, Cleveland Clinic CEO, provides insight to the Supreme Court's ruling on Obamacare subsidies and its impact on patients, hospitals and health insurers.
Despite losing in court, Obamacare critics said the law still has deep flaws.
Ana Gupte, Leerink Partners, weighs in on Obamacare subsidies upheld at a 6-3 vote and the healthcare space.
Deal fever appears to have overtaken the health insurers. And Obamacare may be part of the reason why.
Nearly 75 percent percent of Humana’s revenue comes from Medicare, more than the other big insurers. Here's why Humana is such a hot commodity.
Athena Health CEO Jonathan Bush said that more talks of M&A in health care are just a reflection of slowing innovation in the industry.
Some Oregon insurers want to keep their health plan premium increases moderate for next year, but the state wants them higher.
California's health insurance exchange will collect health insurance data on its 1.4 million customers.
Vishnu Lekraj, Morningstar senior analyst, shares perspective on regulatory hurdles facing consolidation in the health care industry.
CNBC's Bertha Combs reports the details of Cigna's rebuff of Anthem's bid.
Cigna on Sunday rejected an increased $53.8 billion bid from Anthem as inadequate.
Anthem renewed its bid for Cigna, upping its original offer to $184 per share in a deal valued at nearly $53.8 billion.
The extra money comes as some insurers proposed double-digit premium increases for 2016 amid concerns about higher costs.